MeSH term
Frequency | Condition_Probility | Animals | 52 | 0.0 |
Humans | 197 | 0.0 |
Adult | 38 | 0.0 |
Aged | 20 | 0.0 |
Aged, 80 and over | 3 | 0.0 |
Arylsulfotransferase/genetics | 2 | 40.0 |
Case-Control Studies | 10 | 0.0 |
Comparative Study | 21 | 0.0 |
Female | 62 | 0.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
Genotype | 35 | 0.0 |
Glucuronosyltransferase/genetics | 10 | 62.0 |
Middle Aged | 34 | 0.0 |
*Polymorphism, Genetic | 22 | 0.0 |
Research Support, Non-U.S. Gov't | 103 | 0.0 |
Risk Factors | 7 | 0.0 |
Taiwan/epidemiology | 2 | 1.0 |
Gene Frequency | 9 | 0.0 |
Glucuronosyltransferase/*genetics | 58 | 54.0 |
Homozygote | 13 | 0.0 |
Infant, Newborn | 9 | 0.0 |
Male | 57 | 0.0 |
Mutation | 15 | 0.0 |
Reference Values | 4 | 0.0 |
Crigler-Najjar Syndrome/*therapy | 2 | 100.0 |
Gene Expression | 4 | 0.0 |
Liver/metabolism | 2 | 0.0 |
Mice | 8 | 0.0 |
Rats | 20 | 0.0 |
Rats, Gunn | 5 | 38.0 |
Research Support, U.S. Gov't, P.H.S. | 48 | 0.0 |
Time Factors | 9 | 0.0 |
Adolescent | 8 | 0.0 |
Bilirubin/*blood | 5 | 23.0 |
Gilbert Disease/diagnosis/*genetics | 2 | 100.0 |
Polymorphism, Genetic | 22 | 0.0 |
Predictive Value of Tests | 3 | 0.0 |
Promoter Regions (Genetics) | 15 | 0.0 |
Sex Factors | 2 | 0.0 |
Area Under Curve | 2 | 0.0 |
Catalysis | 9 | 1.0 |
Dogs | 3 | 0.0 |
Drug Interactions/physiology | 3 | 9.0 |
Glucuronides/metabolism | 16 | 38.0 |
Glucuronosyltransferase/metabolism | 6 | 22.0 |
Hydrolysis | 2 | 0.0 |
Isoenzymes/metabolism | 9 | 1.0 |
Alamethicin/pharmacology | 2 | 66.0 |
Biotransformation | 9 | 1.0 |
Glucuronides/*metabolism | 7 | 43.0 |
Glucuronosyltransferase/genetics/metabolism | 2 | 15.0 |
In Vitro | 14 | 0.0 |
Intestinal Absorption | 2 | 1.0 |
Microsomes, Liver/drug effects/enzymology/metabolism | 2 | 6.0 |
Cell Line | 11 | 0.0 |
Chromatography, High Pressure Liquid | 10 | 0.0 |
Glucuronosyltransferase/*metabolism | 23 | 41.0 |
Microsomes, Liver/enzymology/metabolism | 4 | 6.0 |
Recombinant Proteins/metabolism | 17 | 0.0 |
Spectrometry, Mass, Electrospray Ionization | 3 | 3.0 |
Magnetic Resonance Spectroscopy | 5 | 0.0 |
Microsomes, Liver/enzymology/*metabolism | 6 | 7.0 |
Structure-Activity Relationship | 5 | 0.0 |
Genetic Predisposition to Disease | 4 | 0.0 |
Alleles | 10 | 0.0 |
Base Sequence | 16 | 0.0 |
Crigler-Najjar Syndrome/*genetics | 3 | 100.0 |
European Continental Ancestry Group | 2 | 0.0 |
*Mutation, Missense | 3 | 0.0 |
Acetylation | 2 | 0.0 |
Bilirubin/*metabolism | 2 | 40.0 |
NF-kappa B/metabolism | 2 | 0.0 |
Cells, Cultured | 10 | 0.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
Gilbert Disease/*genetics | 8 | 72.0 |
*Mutation | 4 | 0.0 |
Syndrome | 3 | 0.0 |
Transcription, Genetic | 3 | 0.0 |
Glucuronosyltransferase/*genetics/metabolism | 7 | 29.0 |
Kinetics | 25 | 0.0 |
Glucuronic Acid/*metabolism | 2 | 66.0 |
Microsomes, Liver/*metabolism | 6 | 3.0 |
Oxidation-Reduction | 5 | 0.0 |
Sulfuric Acid Esters/metabolism | 2 | 50.0 |
Enzyme Induction | 5 | 0.0 |
Glucuronosyltransferase/*biosynthesis | 3 | 30.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 9 | 0.0 |
Tumor Cells, Cultured | 8 | 0.0 |
Microsomes, Liver/metabolism | 11 | 6.0 |
Protein Isoforms | 4 | 0.0 |
Uridine Diphosphate Glucuronic Acid/metabolism | 2 | 50.0 |
Microsomes, Liver/*enzymology/metabolism | 2 | 6.0 |
Spectrum Analysis, Mass | 10 | 1.0 |
Stereoisomerism | 4 | 1.0 |
Substrate Specificity | 14 | 0.0 |
Bilirubin/blood | 6 | 6.0 |
Pedigree | 6 | 0.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
*Promoter Regions (Genetics) | 7 | 0.0 |
English Abstract | 7 | 0.0 |
Crigler-Najjar Syndrome/diagnosis/*genetics | 3 | 100.0 |
Glucuronosyltransferase/deficiency/*genetics | 2 | 100.0 |
Infant | 5 | 0.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
*Gene Therapy | 2 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
Genetic Vectors | 3 | 0.0 |
Child, Preschool | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 9 | 0.0 |
Glucuronosyltransferase/genetics/*physiology | 3 | 75.0 |
Pharmaceutical Preparations/*metabolism | 2 | 2.0 |
Enzyme Inhibitors/pharmacology | 6 | 0.0 |
Glucuronosyltransferase/antagonists & inhibitors/*metabolism | 5 | 62.0 |
Microsomes, Liver/enzymology | 7 | 3.0 |
Molecular Conformation | 2 | 0.0 |
COS Cells | 9 | 0.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
Antineoplastic Agents, Phytogenic/metabolism/*pharmacokinetics | 2 | 66.0 |
Cytochrome P-450 Enzyme System/metabolism | 3 | 1.0 |
DNA Topoisomerases, Type I/antagonists & inhibitors | 2 | 8.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Anticarcinogenic Agents/*pharmacology | 2 | 2.0 |
Blotting, Western | 10 | 0.0 |
Caco-2 Cells | 4 | 1.0 |
Carcinogens/*metabolism | 2 | 2.0 |
Flavonoids/*pharmacology | 2 | 2.0 |
Hydroxylation | 2 | 0.0 |
Imidazoles/metabolism | 2 | 15.0 |
Microsomes/metabolism | 4 | 3.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Cloning, Molecular | 6 | 0.0 |
Exons | 6 | 0.0 |
Isoenzymes/genetics | 4 | 1.0 |
Liver/enzymology | 4 | 0.0 |
Molecular Sequence Data | 16 | 0.0 |
*Multigene Family | 3 | 0.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Sequence Deletion | 5 | 0.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
TATA Box | 7 | 2.0 |
Microsomes/enzymology | 2 | 1.0 |
TATA Box/genetics | 4 | 8.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
European Continental Ancestry Group/genetics | 2 | 0.0 |
Receptors, Estrogen/metabolism | 2 | 0.0 |
Regression Analysis | 2 | 0.0 |
*Variation (Genetics) | 4 | 0.0 |
Transcription Factors/*physiology | 2 | 0.0 |
Transfection | 11 | 0.0 |
Child | 11 | 0.0 |
Hymecromone/metabolism | 2 | 66.0 |
Decision Making | 2 | 2.0 |
Crigler-Najjar Syndrome/enzymology/*genetics | 2 | 100.0 |
Gilbert Disease/enzymology/*genetics | 4 | 100.0 |
Japan | 4 | 0.0 |
Polymerase Chain Reaction | 13 | 0.0 |
DNA Mutational Analysis | 3 | 0.0 |
Taiwan | 2 | 1.0 |
DNA, Complementary | 2 | 0.0 |
Glucuronosyltransferase/genetics/*metabolism | 8 | 22.0 |
Neoplasms/*drug therapy | 2 | 1.0 |
Pharmacogenetics | 4 | 3.0 |
Camptothecin/*analogs & derivatives/*pharmacology | 2 | 18.0 |
*Pharmacogenetics | 4 | 8.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 2 | 0.0 |
Heterozygote | 6 | 0.0 |
Risk | 3 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Bilirubin/metabolism | 9 | 45.0 |
Chromans/*metabolism | 2 | 50.0 |
Rats, Wistar | 5 | 0.0 |
Thiazoles/*metabolism | 2 | 15.0 |
*Thiazolidinediones | 2 | 2.0 |
Estradiol/analogs & derivatives/metabolism | 2 | 50.0 |
Intestines/enzymology | 2 | 11.0 |
Kidney/enzymology | 3 | 2.0 |
Liver/*enzymology | 3 | 0.0 |
Lung/enzymology | 2 | 3.0 |
Tissue Distribution | 4 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
Biological Availability | 2 | 0.0 |
Flavonoids/pharmacology | 2 | 0.0 |
Glucuronosyltransferase/antagonists & inhibitors/metabolism | 2 | 66.0 |
Haplorhini | 2 | 0.0 |
Hydrogen-Ion Concentration | 7 | 0.0 |
Glucuronates/*metabolism | 5 | 23.0 |
Glucuronosyltransferase/chemistry/*metabolism | 3 | 100.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Variation (Genetics) | 9 | 0.0 |
Multivariate Analysis | 3 | 0.0 |
Retrospective Studies | 3 | 0.0 |
Drug Interactions | 3 | 0.0 |
Hamsters | 3 | 0.0 |
Dose-Response Relationship, Drug | 8 | 0.0 |
Glucuronic Acid/metabolism | 2 | 40.0 |
Gilbert Disease/genetics | 2 | 100.0 |
Glucuronosyltransferase/chemistry/*genetics | 2 | 33.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Survival Analysis | 2 | 0.0 |
Multigene Family | 2 | 0.0 |
Glucuronidase/metabolism | 2 | 6.0 |
DNA Primers | 7 | 0.0 |
Blotting, Northern | 4 | 0.0 |
Isoenzymes/genetics/metabolism | 3 | 2.0 |
Microsomes, Liver/*enzymology | 6 | 3.0 |
Cytochrome P-450 Enzyme System/*metabolism | 2 | 0.0 |
Isoenzymes/*metabolism | 2 | 0.0 |
Liver/drug effects/enzymology/metabolism | 2 | 16.0 |
Species Specificity | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 3 | 0.0 |
Mycophenolic Acid/*metabolism | 2 | 66.0 |
Dinucleotide Repeats | 2 | 2.0 |
Ethnic Groups/genetics | 2 | 1.0 |
Benzidines/*metabolism | 2 | 100.0 |
Enzyme Stability | 2 | 1.0 |
Linkage Disequilibrium | 2 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Chromatography, Liquid | 5 | 4.0 |
United States | 2 | 0.0 |
Cross-Sectional Studies | 2 | 0.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
Gene Expression Regulation, Enzymologic | 4 | 0.0 |
*TATA Box | 2 | 1.0 |
Transcription, Genetic/drug effects | 3 | 0.0 |
Amino Acid Sequence | 8 | 0.0 |
Liver/cytology/*enzymology | 2 | 10.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Glucuronosyltransferase/analysis/*genetics | 2 | 100.0 |
Prospective Studies | 4 | 0.0 |
Camptothecin/*analogs & derivatives/metabolism | 3 | 100.0 |
Glucuronidase/*metabolism | 2 | 33.0 |
Antineoplastic Agents, Phytogenic/*metabolism | 2 | 20.0 |
Phenotype | 5 | 0.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
*Gene Expression Regulation, Enzymologic | 6 | 1.0 |
Glucuronosyltransferase/*genetics/*metabolism | 2 | 28.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Glucuronosyltransferase/*biosynthesis/*genetics | 3 | 100.0 |
Stomach/*enzymology | 2 | 22.0 |
Rabbits | 2 | 0.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Gilbert Disease/*enzymology/*genetics | 2 | 100.0 |
Sequence Alignment | 2 | 0.0 |
Introns | 2 | 0.0 |
Isoenzymes/genetics/*metabolism | 2 | 2.0 |
Nitrophenols/metabolism | 2 | 9.0 |
Cell Line, Tumor | 4 | 0.0 |
Binding Sites | 3 | 0.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Models, Chemical | 3 | 0.0 |
Phosphorylation | 2 | 0.0 |
Cytochrome P-450 Enzyme System/genetics/metabolism | 2 | 4.0 |
Enzyme Induction/drug effects | 2 | 0.0 |
Glucuronosyltransferase/*biosynthesis/genetics | 3 | 33.0 |
Chromosome Mapping | 4 | 0.0 |
Cytochrome P-450 Enzyme System/genetics | 4 | 3.0 |
Isoenzymes/biosynthesis/genetics | 2 | 4.0 |
Xenobiotics/*pharmacology | 2 | 6.0 |
Antineoplastic Agents, Phytogenic/*adverse effects | 2 | 50.0 |
*Chromosomes, Human, Pair 2 | 3 | 1.0 |
Lod Score | 2 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Confidence Intervals | 2 | 0.0 |
Drug Administration Schedule | 2 | 0.0 |
Pharmacogenetics/*methods | 3 | 17.0 |
Cercopithecus aethiops | 2 | 0.0 |
Jaundice, Neonatal/enzymology/*genetics | 2 | 100.0 |
Methyltransferases/genetics | 3 | 17.0 |
Glucuronides/chemistry/*metabolism | 2 | 33.0 |
Amino Acid Substitution/genetics | 2 | 0.0 |
